Avior Wealth Management LLC Acquires 240 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Avior Wealth Management LLC raised its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 3.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 8,212 shares of the biotechnology company’s stock after buying an additional 240 shares during the period. Avior Wealth Management LLC’s holdings in Ascendis Pharma A/S were worth $1,226,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ASND. Avoro Capital Advisors LLC boosted its holdings in shares of Ascendis Pharma A/S by 5.8% in the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock valued at $572,341,000 after buying an additional 229,995 shares during the last quarter. Capital International Investors raised its position in Ascendis Pharma A/S by 0.5% during the first quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company’s stock worth $331,261,000 after acquiring an additional 10,044 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in Ascendis Pharma A/S by 23.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock worth $269,374,000 after acquiring an additional 336,976 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its stake in Ascendis Pharma A/S by 5.8% in the second quarter. Massachusetts Financial Services Co. MA now owns 1,711,015 shares of the biotechnology company’s stock valued at $233,348,000 after acquiring an additional 93,185 shares during the last quarter. Finally, Fred Alger Management LLC grew its position in shares of Ascendis Pharma A/S by 65.0% in the 2nd quarter. Fred Alger Management LLC now owns 307,073 shares of the biotechnology company’s stock valued at $41,879,000 after acquiring an additional 120,952 shares during the period.

Ascendis Pharma A/S Stock Down 0.0 %

Shares of NASDAQ:ASND opened at $124.38 on Thursday. Ascendis Pharma A/S has a 12-month low of $90.13 and a 12-month high of $161.00. The company’s 50 day moving average price is $132.82 and its two-hundred day moving average price is $132.32. The firm has a market cap of $7.54 billion, a PE ratio of -15.39 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The business had revenue of $38.75 million during the quarter, compared to analysts’ expectations of $94.74 million. On average, research analysts expect that Ascendis Pharma A/S will post -7.3 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. cut their target price on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating for the company in a research note on Wednesday, October 23rd. The Goldman Sachs Group raised their price objective on Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th. Wells Fargo & Company boosted their target price on Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an “overweight” rating in a report on Tuesday, September 17th. Citigroup raised their price target on Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a report on Tuesday, September 17th. Finally, Bank of America lifted their price objective on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, Ascendis Pharma A/S presently has an average rating of “Moderate Buy” and a consensus price target of $191.77.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.